Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 1/20 | 0.49 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.36 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978016 | 1.00 | GRN (0.49) | GRNSORT1MAPK1KEAP1PYGL | |
| Hydrochloric Acid SCHEMBL5226312 | 0.98 | GRN (0.48) | GRNSORT1MAPK1KEAP1PYGL | |
| SCHEMBL13166785 | 0.82 | MAPK1 (0.39) | GRNSORT1MAPK1 | |
| SCHEMBL27420062 | 0.82 | MAPK1 (0.39) | GRNSORT1MAPK1 | |
| SCHEMBL20850028 | 0.82 | MAPK1 (0.39) | GRNSORT1MAPK1 | |
| SCHEMBL26229150 | 0.82 | GRN (0.38) | GRNSORT1MAPK1PYGLCYP2C9 | |
| SCHEMBL20980672 | 0.82 | MME (0.38) | GRNSORT1TGFBR1KDM4EMAPT | |
| SCHEMBL1693987 | 0.82 | GRN (0.50) | GRNSORT1MAPK1KEAP1PYGL | |
| SCHEMBL5048325 | 0.82 | GRN (0.50) | GRNSORT1MAPK1KEAP1PYGL | |
| SCHEMBL1693084 | 0.82 | GRN (0.50) | GRNSORT1MAPK1KEAP1PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4406606-A2 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE G | Bayer Pharma Aktiengesellschaft (DE) | 2024-07-31 | — | — | EP | disclosed |
| CN-108794422-B | Heterocyclic compounds as PD-L1 inhibitors | 南京圣和药业股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| EP-3432934-B1 | PRODRUGS OF CYTOTOXIC AGENTS WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma AG (DE) | 2022-02-23 | — | — | EP | disclosed |
| EP-3432934-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2019-01-30 | — | — | EP | disclosed |
| EP-3313521-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-TWEAKR-ANTIBODIES | Bayer Pharma Aktiengesellschaft (DE) | 2018-05-02 | — | — | EP | disclosed |
| EP-3313525-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | Bayer Pharma Aktiengesellschaft (DE) | 2018-05-02 | — | — | EP | disclosed |
| EP-3313524-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-CD123-ANTIBODIES | Bayer Pharma Aktiengesellschaft (DE) | 2018-05-02 | — | — | EP | disclosed |
| EP-3313522-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | Bayer Pharma Aktiengesellschaft (DE) | 2018-05-02 | — | — | EP | disclosed |
| EP-3310440-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2018-04-25 | — | — | EP | disclosed |
| EP-3233127-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | Bayer Pharma Aktiengesellschaft (DE) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016207098-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-CD123-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016207103-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016096610-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | WO | disclosed |
| US-8609836-B2 | 4-aryl-2-anilino-pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-17 | — | — | US | disclosed |
| EP-2283024-B1 | 4-ARYL-2-ANILINO-PYRIMIDINES AS PLK KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-15 | — | — | EP | disclosed |
| US-20130053379-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-28 | — | — | US | disclosed |
| US-8318929-B2 | 4-aryl-2-anilino-pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-27 | — | — | US | disclosed |
| EP-2283024-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES AS PLK KINASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2011-02-16 | — | — | EP | disclosed |
| US-20110009404-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-13 | — | — | US | disclosed |
| WO-2009112439-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES AS PLK KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053379-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES | PLK4, PLK3, PLK2 | GRN 4043/4885SORT1 2540/4885MAPK1 202/4885 |
| US-20110009404-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES | PLK4, PLK3, PLK2 | GRN 4043/4885SORT1 2540/4885MAPK1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.